Fulcrum Therapeutics Inc (NAS:FULC)
$ 7.47 -0.03 (-0.4%) Market Cap: 464.29 Mil Enterprise Value: 238.89 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 48/100

Fulcrum Therapeutics, Inc. - Special Call Transcript

Dec 15, 2020 / 01:30PM GMT
Release Date Price: $13.4 (+0.37%)
Christi Waarich
Fulcrum Therapeutics, Inc. - Director of Corporate Communications & IR

Good morning, and thank you for joining Fulcrum Therapeutics Virtual KOL event featuring FTX-6058 for sickle cell disease. I'm Christi Waarich, Director of Investor Relations and Corporate Communications.

Just a few words before we get started. This is our disclaimer. Please refer to our most recent filings with the SEC for a discussion of certain risks and uncertainties associated with our business.

Before I turn it over to Robert Gould, Fulcrum's President and CEO, I'd like to remind you that today's presentation will be followed by a Q&A session. (Operator Instructions)

Thank you again for joining us. I'd now like to turn it over to Robert. Robert?

Robert J. Gould
Fulcrum Therapeutics, Inc. - CEO, President & Director

Thank you, Christi, and thank you, everybody, for joining us on this webinar on our sickle cell disease program. We're very excited to present this program to you today for 2 reasons. First of all, for the potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot